期刊文献+

不同剂量阿托伐他汀对冠状动脉内支架植入术后血清单核细胞趋化蛋白-1、白细胞介素-10和高敏C反应蛋白水平的影响 被引量:3

Effect of different-dose atorvastatins on serum High sensitive C-reactive protein, Interleukin-10 and Monncyte chemoattractant protein-1 levels in post-intervention patients with coronary stenting
原文传递
导出
摘要 目的 观察不同剂量阿托伐他汀对经皮冠脉内支架植入术(PCI)术后血清单核细胞趋化蛋白-1(MCP-1)、白细胞介素-10(IL-10)和高敏C反应蛋白(hs-CRP)水平的影响. 方法 选择PCI术后冠心病患者93例,按数字表法随机分成三组,每组31例,三组分别于术后给予阿托伐他汀10 mg、20 mg和40 mg口服,每天1次,持续服药1周以上,于术前及术后24 h、1周分别采集患者静脉血,测定MCP-1、IL-10和hs-CRP水平. 结果 三组术后24小时血清hsCR、MCP-1、IL-10水平较术前明显升高(t=7.231、9.516、3.612、8.254、9.365、4.125、8.473、8.342、4.106,均P<0.01);术后1周,三组hsCR、MCP-1水平较术后24 h明显降低(t=5.204、5.651、3.251、4.174、5.301、4.761,均P<0.01);术后1周,三组血清hsCR、MCP-1、IL-10、MCP-1/IL-10水平间差异均有统计学意义(F=27.625、43.396、3.486、44.961,均P<0.01);经直线相关分析,hs-CRP、MCP-1水平和MCP-1/IL-10比值与阿托伐他汀剂量呈负相关关系(hs-CRP:r=-0.617;MCP-1:r=-0.682;MCP-1/IL-10:r=-0.584,均P<0.01),IL-10与阿托伐他汀剂量无相关关系(r=0.138,P=0.187). 结论 阿托伐他汀可降低PCI术后患者血清hs-CRP和MCP-1水平,其剂量与hs-CRP和MCP-1水平呈负相关. Objective To Discuss the impacts of different dosage of atorvastatirs on serum hsCRP,IL-10 and MCP-1 levels on post-intervention patients with coronary stenting. Methods 93 post-intervention patients with coronary stenting were selected and randomly divided into 3 groups.Each group took different dosage of oral atorvastatins after the operation for more than one week.The dosage for each group was 10 mg,20 mg and 40 mg,respectively.Each patient was phlebotomized for three times,which are 24 hours before the operation,24 hours after the operation and one week after the operation.Serum MCP-1,IL-10 and hs-CRP levels were measured by enzyme linked immunosorbent assay(ELISA)and immunoturbidimetry(ITM). Results Serum hs-CRP and MCP-1 levels of post-intervention patients were significantly higher than those of pre-intervention.This illustrated that the serum hsCRP and MCP-1 levels were closely related to PCI.Serum hs-CRP and MCP-1 levels decreased in those patients one week after operation which proves they are negatively correlated with the dosage of atorvastatins.There was no statistic evidence to prove the correlation between different dosage of atorvastatins and the level of serum IL-10.The ratio of MCP-1/IL-10 at 24h post-intervention patient was significantly higher than pre-intervention,which proves the ratio was negatively correlated with the dosage of atorvastatins. Conclusion Atorvastatins decreases serum MCP-1 and hs-CRP levels after PCI.Serum MCP-1 and hs-CRP levels were negatively correlated with the dosage of atorvastatins.
出处 《中国基层医药》 CAS 2010年第16期2176-2178,共3页 Chinese Journal of Primary Medicine and Pharmacy
关键词 血管成形术 经腔 经皮冠状动脉 C反应蛋白质 单核细胞趋化蛋白质类 白细胞介素10 阿托伐他汀 Angioplasty,transluminal,percutaneous coronary C-Reactive prolein Monocyte chemoatt ractant proteins Interleukin-10 Atorvastatin
  • 相关文献

参考文献18

  • 1Komowski R,Hone M,Fenmin F,et al.Instent restenosis contributions of inflammatory responscs and arterial injury to neointimal hyperprlasia.J Am Coll Cardiol,2003,31(1):224-230.
  • 2Gu I,Tseng S,Rollins B.Monocyte chemcoattractant protein-1.Chem Immunol,2003,72(1):27-29.
  • 3Cipollone F,Marini M,Fuzia M,et al.Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty.Armterioscler Thromb Vasc Biol,2004,21(3):327-334.
  • 4DE-Winter RJ,Fischet JC,DE-Jongh T,et al.Different time frames for the occurrence of elevated leves of cardiac troponins T and C-reactive protein inpatient swith acute myocardial infarction.Clin Chem Lad Med,2000,38(11):1151-1153.
  • 5Mockel M,Heller G,Muller C,et al.C-reactive protive as an independent marker of prognosis in acute coronary syndrome.Z Kardiol,2000,89(8):658-666.
  • 6Bybee KY,Wright RS,Kopecky SL.Effect of early statin therapy after actue coronary syndromes:a concise review of the recent data.Cardiol Rew,2002,10(5):301-305.
  • 7Water DD.Early pharmacologic intervention and plaque stability in acute coronary syndromes.Am J Cardiol,2001,88(8A):30K-36K.
  • 8迪丽努尔·塔吉,张妍.阿托伐他汀短期强化降脂治疗对冠心病高危人群血脂的影响及安全性评价[J].中国基层医药,2009,16(8):1482-1483. 被引量:7
  • 9Libhy P.Current concepts pathogenesis of the acute coronary syndromes.Circulation,2001,104(5):365-372.
  • 10The Scandinavian Simvastatin Survival Study Group.Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival study(4S).Lancet,1994,344(8934):1383-1389.

二级参考文献35

  • 1宋月彬.丹奥治疗急性冠脉综合症的临床研究[J].中国医疗前沿(学术版),2008,3(2):70-71. 被引量:7
  • 2张世阳,王卫东,谈敏.阿托伐他汀积极降脂改善临床预后[J].中国临床保健杂志,2006,9(1):88-90. 被引量:20
  • 3朱喜玲,陈金钟.阿托伐他汀对急性脑梗死患者血浆一氧化氮及血小板α颗粒膜蛋白水平的影响[J].中国基层医药,2006,13(7):1071-1072. 被引量:21
  • 4杜坚宗,董碧蓉.阿托伐他汀钙防治大鼠肺缺血再灌注损伤的实验研究[J].中国基层医药,2006,13(12):2027-2028. 被引量:5
  • 5Wang J, Rogove AD, Tsirka AE, et al. Protective role of tuftsin fragmentl 3 in an animal nodel of intracerebral hemorrhage. Ann Neurol,2003 ,54 :655-664.
  • 6Xi G, Hua Y, Keep RF, et al. Systemic complement depletion diminishes perihematomal brain edema. Stroke,2001,32 : 162-167.
  • 7Stanimirovic D, Shapiro A, Wong J, et al. The induction of ICAM-1 in human cerebromicrovascular endothelial cells(HCEC) by ischemic-like conditions promotes enhanced neutrophil/HCEC adhesion. Neuroimmunol, 1997,76 ( 1-2 ) : 193-205.
  • 8Mallat I, Heymes C,Ohan J,et al. Expression of interleukin-10 in advanced human atheresclerotic plaques:relation to inducible nitric, oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol,1999,19(3) :611-616.
  • 9Jian-Jnn Li, Chun-Hong Fang. Effects of 4 weeks of atorvastain administration on the antiinflammatory cytokine interleukin-10 in patients with unstable angina. Clinical Chemistry, 2005,51 ( 9 ) : 1735-1738.
  • 10Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation ,2001,103 : 1191 -1193.

共引文献28

同被引文献37

  • 1朱喜玲,陈金钟.阿托伐他汀对急性脑梗死患者血浆一氧化氮及血小板α颗粒膜蛋白水平的影响[J].中国基层医药,2006,13(7):1071-1072. 被引量:21
  • 2高洁,盖萍,沙晶,陈良华,朱兴雷.冠状动脉狭窄程度与高敏C反应蛋白的相关性研究[J].山东医药,2006,46(28):11-11. 被引量:4
  • 3郑茂,叶山东.单核细胞趋化蛋白-1与糖尿病肾病[J].国际病理科学与临床杂志,2007,27(3):253-256. 被引量:3
  • 4Tanaka A,Kawarabayashi T,Nishibori Y,et al. No-reflow phenomenon and lesion morphology in patients with acute myocardial infarction. Circulation, 2002,105 ( 18 ) : 2148-2152.
  • 5Brosh D,Assali AR,Mager A,et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol, 2007,99 (4):442-445.
  • 6Kloner RA. Does reperfusion injury exist in humans? J Am CoilCardiol, 2003, 21 (2) : 537-545.
  • 7Brener SJ,EUis SG,Schneider J,et al. Frequency and long-term impact of myonecresiS after coronary stenting. Eur Heart J, 2002,23 ( 11 ) : 869-876.
  • 8Nallamothu BK, Bates ER. Periprocedural myocardial infarction and mortality: causality versus association. J Am Coil Cardiol,2003,42 ( 8 ) : 1412-1414.
  • 9Patti G,Pasceri V,Colonna G,et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coil Cardiol,2007, 49 (12) : 1272-1278.
  • 10Chyrchel M,Rakowski T,Rzeszutko L,et al. Effects of high-dase statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome. Kardiol Pol, 2006,64( 12): 1357-1362.

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部